Package Leaflet: Information for the User
Dexdor 100micrograms/ml concentrate for solution for infusion
dexmedetomidine
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack and other information:
Dexdor contains the active substance dexmedetomidine, which belongs to a group of medicines called sedatives. It is used to provide sedation (a state of calm, drowsiness or sleep) in adult patients in intensive care units in hospitals or conscious sedation during various diagnostic or surgical procedures.
Dexdor must not be given to you
Warnings and precautions
Before using this medicine, tell your doctor or nurse if you are in any of the following situations, as Dexdor should be used with caution:
Using Dexdor with other medicines
Tell your doctor or nurse if you are using, have recently used or might use any other medicines.
The following medicines may increase the effect of Dexdor:
If you are using medicines that lower your blood pressure and heart rate, taking them with Dexdor may increase this effect. Dexdor should not be used with medicines that can cause temporary paralysis.
Pregnancy and breast-feeding
Dexdor should not be used during pregnancy or breast-feeding, unless clearly necessary.
Ask your doctor before using this medicine.
Driving and using machines
Dexdor has a major impact on your ability to drive and use machines. Once you have been given Dexdor, you should not drive, operate machinery or work in hazardous situations until the effects have passed completely. Consult your doctor when you can resume these activities and this type of work.
Excipients
Dexdor contains less than 1 mmol of sodium (23 mg) per ml; this is essentially “sodium-free”.
Intensive care in hospital
Dexdor is given to you by a doctor or nurse in the intensive care unit of a hospital.
Procedural sedation / conscious sedation
Dexdor is given to you by a doctor or nurse before and/or during diagnostic or surgical procedures that require sedation, e.g. procedural sedation / conscious sedation.
Your doctor will decide the right dose for you. The amount of Dexdor depends on your age, body weight, overall health, the level of sedation needed and how you respond to the medicine. Your doctor may change your dose if necessary and will monitor your heart and blood pressure during treatment.
Dexdor is diluted and given to you as an infusion (drip) into your veins.
After sedation/waking up
If you have been given too much Dexdor
If you have been given too much Dexdor, your blood pressure may go up or down, your heart beats may be slower, you may breathe more slowly and you may feel more drowsy. Your doctor will know how to treat you based on your condition.
If you have any other questions about the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common (affect more than 1 in 10 users)
Common (affect between 1 and 10 in 100 users)
Uncommon (affect between 1 and 10 in 1,000 users)
Rare (cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor or nurse, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP.
This medicine does not require any special storage conditions. Store the ampoules or vials in the outer packaging to protect from light.
Composition of Dexdor
Each 2 ml ampoule contains 200 micrograms of dexmedetomidine (as hydrochloride).
Each 2 ml vial contains 200 micrograms of dexmedetomidine (as hydrochloride).
Each 4 ml vial contains 400 micrograms of dexmedetomidine (as hydrochloride).
Each 10 ml vial contains 1000 micrograms of dexmedetomidine (as hydrochloride).
The concentration of the final solution after dilution should be 4 micrograms/ml or 8 micrograms/ml.
Appearance and pack size
Concentrate for solution for infusion (sterile concentrate).
The concentrate is a clear and colorless solution
Pack sizes
2 ml glass ampoules
2, 5 or 10 ml glass vials
Pack sizes
5 ampoules of 2 ml
25 ampoules of 2 ml
5 vials of 2 ml
4 vials of 4 ml
4 vials of 10 ml
Not all pack sizes may be marketed.
Marketing authorisation holder
Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland
Manufacturer
Orion Corporation Orion Pharma
Orionintie 1
FI-02200 Espoo
Finland
You can get more information about this medicine from your local representative of the marketing authorisation holder:
België/Belgique/Belgien Luxembourg/Luxemburg Orion Pharma BVBA/SPRL Tel: +32 (0)15 64 10 20 | |
Nederland Orion Pharma BVBA/SPRL Tel: +32 (0)15 64 10 20 | Danmark Orion Pharma A/S Tlf: + 45 8614 00 00 |
Ceská republika Orion Pharma s.r.o. Tel: +420 234 703 305 | Eesti Orion Pharma Eesti Oü Tel: +372 6 644 550 |
Deutschland Österreich Orion Pharma GmbH Tel: + 49 40 899 6890 | España Orion Pharma S.L. Tel: + 34 91 599 86 01 |
Ελλάδα Orion Pharma Hellas M.E.Π.E Τηλ: + 30 210 980 3355 | Ireland Orion Pharma (Ireland) Ltd. Tel: + 353 1 428 7777 |
France Centre Spécialités Pharmaceutiques Tel: + 33 (0) 1 47 04 80 46 | Italia Orion Pharma S.r.l. Tel: + 39 02 67876111 |
Ísland Vistor hf. Simi: +354 535 7000 | Latvija Orion Corporation in Latvia Tel: + 371 6745 5569 |
Κύπρος Lifepharma (ZAM) Ltd Τηλ.: +357 22347440 | Magyarország Orion Pharma Kft. Tel.: +36 1 239 9095 |
Lietuva UAB Orion Pharma Tel: +370 5 276 9499 | Polska Orion Pharma Poland Sp. z.o.o. Tel.: + 48 22 8 333 177 |
Norge Orion Pharma AS Tlf: + 47 4000 4210 | Slovenija Orion Pharma d.o.o. Tel: +386 (0) 1 600 8015 |
Portugal Orionfin Unipessoal Lda Tel: + 351 21 154 68 20 | Suomi/Finland Orion Corporation Puh/Tel: + 358 10 4261 |
?????? Orion Pharma Poland Sp. z.o.o. ???.: + 48 22 8 333 177 | Hrvatska PHOENIX Farmacija d.o.o. Tel: +385 1 6370450 |
Malta Orion Corporation Tel: + 358 10 4261 | România Orion Corporation Tel: + 358 10 4261 |
Slovenská republika Orion Pharma s.r.o. Tel: +420 234 703 305 | United Kingdom Orion Pharma (UK) Ltd. Tel: + 44 1635 520 300 |
Sverige Orion Pharma AB Tel: + 46 8 623 6440 |
Date of last revision of this leaflet
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
-----------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Dexdor 100micrograms/ml concentrate for solution for infusion
Method of administration
Dexdor should be administered by healthcare professionals experienced in the management of patients requiring intensive care or anaesthesia management in the operating room. It should be administered only as a diluted intravenous infusion using a controlled infusion device.
Preparation of the solution
Dexdor can be diluted in glucose 50 mg/ml (5%), Ringer’s solution, mannitol or sodium chloride 9 mg/ml (0.9%) injection solution to achieve the required concentration of 4 micrograms/ml or 8 micrograms/ml before administration. See below in the form of a table the volumes needed to prepare the infusion.
In case a concentration of 4 micrograms/ml is required:
Volume of Dexdor 100micrograms/ml concentrate for solution for infusion | Volume of diluent | Total volume of infusion |
2 ml | 48 ml | 50 ml |
4 ml | 96 ml | 100 ml |
10 ml | 240 ml | 250 ml |
20 ml | 480 ml | 500 ml |
In case a concentration of 8micrograms/ml is required:
Volume of Dexdor 100micrograms/ml concentrate for solution for infusion | Volume of diluent | Total volume of infusion |
4 ml | 46 ml | 50 ml |
8 ml | 92 ml | 100 ml |
20 ml | 230 ml | 250 ml |
40 ml | 460 ml | 500 ml |
The solution should be gently shaken to mix well.
Dexdor should be visually inspected for particles and coloration before administration.
Dexdor has been shown to be compatible when administered with the following intravenous fluids and medicines:
Ringer’s solution, glucose 5% solution, sodium chloride 9 mg/ml (0.9%) injection solution, mannitol 200 mg/ml (20%), thiopental sodium, etomidate, vecuronium bromide, pancuronium bromide, succinylcholine, atracurium besylate, mivacurium chloride, rocuronium bromide, glycopyrrolate, phenylephrine HCl, atropine sulfate, dopamine, noradrenaline, dobutamine, midazolam, morphine sulfate, fentanyl citrate, and a plasma substitute.
Compatibility studies have shown potential for adsorption of dexmedetomidine to some types of natural rubber. Although dexmedetomidine is dosed to effect, it is recommended to use components with synthetic or natural rubber gaskets.
Shelf life
Chemical and physical stability in use has been demonstrated for 24 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2° to 8°C, unless the dilution has been made in controlled and validated aseptic conditions.